Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Uterine Cervical Neoplasms 2 Kidney Neoplasms 2 Carcinoma, Renal Cell 2 Triple Negative Breast Neoplasms 1 Thyroid Carcinoma, Anaplastic 1 Thymoma 1 Solid Tumor 1 Rectal Neoplasms 1 Oligometastatic Prostate Cancer 1 Neoplasms 1 Metastatic Urothelial Cancer 1 Lung Diseases 1 Locally Advanced Cervical Cancer 1 Gestational Trophoblastic Disease 1 Gastro-enteropancreatic neuroendocrine tumor 1 Erythrocytosis, Familial, 4 1 Cholangiocarcinoma 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoid Tumor 1 Breast Neoplasms 1 Bile Duct Neoplasms 1 Advanced Solid Tumors 1 Advanced Solid Tumor 1

Interventions

Carboplatin 5 Cisplatin 3 zipalertinib 1 zimberelimab 1 sacituzumab govitecan 1 repotrectinib 1 pembrolizumab 1 cemiplimab 1 atezolizumab 1 alectinib 1 Vital Signs 1 Tomography, Emission-Computed, Single-Photon 1 Toll-Like Receptor 1 1 Telescopes 1 Radiotherapy 1 Radiosurgery 1 Pemetrexed 1 Paclitaxel 1 Magnetic Resonance Spectroscopy 1 Etoposide 1 Drug Delivery Systems 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Lung Diseases × zimberelimab × Clear all

NCT06431633 2026-05-18

ARIAN

Fundación GECP

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Diseases

Data powered by HemOnc (CC BY 4.0) Colophon ⚡